Janus portfolio manager sees more biotech gains on Trump

NEW YORK (Reuters) - Biotech stocks still have room to rise after the election of Donald Trump as U.S. president, which removed threats of drug price controls that had pushed shares to historically cheap levels this year, a top portfolio manager for Janus said on Wednesday.

Janus portfolio manager sees more biotech gains on Trump
Read More


Bagikan Berita Ini